Relative trials were identified in the PubMed, The Web of Science, OVID EBM Reviews and Cochrane databases, and the relevant papers were examined. Pooled mean difference (MD) and 95% confidence interval (95% CI) were estimated by random effects models. The primary endpoints in our meta-analysis were renal function, determined by blood urea, creatinine levels, eGFR and urine output. Secondary endpoints were rates of all-cause mortality and readmission after treatment.
Six randomized controlled trials (RCTs) and one retrospective study involving 587 patients were included in this analysis. LDD enhanced eGFR (MD, 7.44; 95% CI, 1.92–12.95; P = 0.008), urine output (SMD, 0.58; 95% CI, 0.15–1.01; P = 0.008) and decrease creatinine levels (MD, − 0.36; 95% CI, − 0.64/− 0.08; P = 0.004), blood urea (MD, − 6.97; 95% CI, − 13.12/− 0.81; P = 0.03). No statistically significant differences in the rates of mortality (RR, 0.86; 95% CI, 0.62–1.20, P = 0.37) and readmission (RR: 0.86; 95% CI 0.47–1.56, P = 0.62) were noted.
LDD indeed brought benefits in terms of promoting diuresis and preserving renal function for HF patients. It did not demonstrate statistical significance in rates of readmission nor mortality. The efficacy of LDD to HF patients should be confirmed by further large, high quality clinical trials.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址:北京市海淀区学院路29号 邮编:100083 电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700 |